286 related articles for article (PubMed ID: 28578142)
1. Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy.
Kim Y; Squires MH; Poultsides GA; Fields RC; Weber SM; Votanopoulos KI; Kooby DA; Worhunsky DJ; Jin LX; Hawkins WG; Acher AW; Cho CS; Saunders N; Levine EA; Schmidt CR; Maithel SK; Pawlik TM
Surgery; 2017 Aug; 162(2):285-294. PubMed ID: 28578142
[TBL] [Abstract][Full Text] [Related]
2. Impact of external-beam radiation therapy on outcomes among patients with resected gastric cancer: a multi-institutional analysis.
Ejaz A; Spolverato G; Kim Y; Squires MH; Poultsides G; Fields R; Bloomston M; Weber SM; Votanopoulos K; Worhunsky DJ; Swords D; Jin LX; Schmidt C; Acher AW; Saunders N; Cho CS; Herman JM; Maithel SK; Pawlik TM
Ann Surg Oncol; 2014 Oct; 21(11):3412-21. PubMed ID: 24845728
[TBL] [Abstract][Full Text] [Related]
3. Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer.
Hwang JE; Kim H; Shim HJ; Bae WK; Hwang EC; Jeong O; Ryu SY; Park YK; Cho SH; Chung IJ
J Cancer Res Clin Oncol; 2019 Aug; 145(8):2157-2166. PubMed ID: 31273512
[TBL] [Abstract][Full Text] [Related]
4. The addition of chemoradiation to adjuvant chemotherapy is associated with improved survival in lymph node-positive gastric cancer.
Altman AM; Sheka AC; Marmor S; Lou E; Reynolds M; Hui JYC; Tuttle TM; Jensen EH; Denbo JW
Surg Oncol; 2020 Sep; 34():134-139. PubMed ID: 32891318
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy.
In H; Kantor O; Sharpe SM; Baker MS; Talamonti MS; Posner MC
Ann Surg Oncol; 2016 Jun; 23(6):1956-62. PubMed ID: 26753752
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
Cats A; Jansen EPM; van Grieken NCT; Sikorska K; Lind P; Nordsmark M; Meershoek-Klein Kranenbarg E; Boot H; Trip AK; Swellengrebel HAM; van Laarhoven HWM; Putter H; van Sandick JW; van Berge Henegouwen MI; Hartgrink HH; van Tinteren H; van de Velde CJH; Verheij M;
Lancet Oncol; 2018 May; 19(5):616-628. PubMed ID: 29650363
[TBL] [Abstract][Full Text] [Related]
7. Multimodality Therapy Improves Survival in Resected Early Stage Gastric Cancer in the United States.
Datta J; McMillan MT; Ruffolo L; Lowenfeld L; Mamtani R; Plastaras JP; Dempsey DT; Karakousis GC; Drebin JA; Fraker DL; Roses RE
Ann Surg Oncol; 2016 Sep; 23(9):2936-45. PubMed ID: 27090793
[TBL] [Abstract][Full Text] [Related]
8. Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States: A Propensity Score-matched Analysis.
Datta J; McMillan MT; Ecker BL; Karakousis GC; Mamtani R; Plastaras JP; Giantonio BJ; Drebin JA; Dempsey DT; Fraker DL; Roses RE
Ann Surg; 2016 Feb; 263(2):298-305. PubMed ID: 26135687
[TBL] [Abstract][Full Text] [Related]
9. [Adjuvant chemo radiotherapy after gastrectomy and D2 lymphadenectomy in patients with gastric cancer in the National Institute of Cancer, Lima, Peru].
Montenegro P; Flores L; Quintana S; Casanova L; Ruíz E; León J; Mantilla R
Rev Gastroenterol Peru; 2013; 33(1):34-8. PubMed ID: 23539054
[TBL] [Abstract][Full Text] [Related]
10. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
[No Abstract] [Full Text] [Related]
11. Combination 5-fluoruracil/cisplatinum versus 5-fluoruracil/leucovorin adjuvant chemotherapy efficacy for R0 gastric resection in locally invasive gastric cancer.
Yamada S; Ritchim P; Charkrabandhu T; Jongraksat W
J Med Assoc Thai; 2012 Dec; 95(12):1517-23. PubMed ID: 23390781
[TBL] [Abstract][Full Text] [Related]
12. Factors Associated With Recurrence and Survival in Lymph Node-negative Gastric Adenocarcinoma: A 7-Institution Study of the US Gastric Cancer Collaborative.
Jin LX; Moses LE; Squires MH; Poultsides GA; Votanopoulos K; Weber SM; Bloomston M; Pawlik TM; Hawkins WG; Linehan DC; Strasberg SM; Schmidt C; Worhunsky DJ; Acher AW; Cardona K; Cho CS; Kooby DA; Levine E; Winslow ER; Saunders ND; Spolverato G; Maithel SK; Fields RC
Ann Surg; 2015 Dec; 262(6):999-1005. PubMed ID: 25607760
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant radiation therapy increases overall survival in node-positive gastric cancer patients with aggressive surgical resection and lymph node dissection: a SEER database analysis.
Shridhar R; Dombi GW; Weber J; Hoffe SE; Meredith K; Konski A
Am J Clin Oncol; 2012 Jun; 35(3):216-21. PubMed ID: 21378540
[TBL] [Abstract][Full Text] [Related]
14. Postoperative adjuvant treatment for gastric cancer improves long-term survival after curative resection and D2 lymphadenectomy. Results from a Latin American Center.
Norero E; Bustos M; Herrera ME; Cerda J; González P; Ceroni M; Martínez C; Briceño E; Rojas H; Cártes R; Lopez V; Hidalgo V; Báez S; Caracci M; Viñuela E; Díaz A
Eur J Surg Oncol; 2016 Jan; 42(1):94-102. PubMed ID: 26577767
[TBL] [Abstract][Full Text] [Related]
15. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
[No Abstract] [Full Text] [Related]
16. Adjuvant chemoradiotherapy after d2-lymphadenectomy for gastric cancer: the role of n-ratio in patient selection. results of a single cancer center.
Costa WL; Coimbra FJ; Fogaroli RC; Ribeiro HS; Diniz AL; Begnami MD; Mello CA; Fanelli MF; Silva MJ; Fregnani JH; Montagnini AL
Radiat Oncol; 2012 Oct; 7():169. PubMed ID: 23068190
[TBL] [Abstract][Full Text] [Related]
17. Lymph Node Burden as a Predictive Factor for Selective Chemoradiotherapy in Patients With Locally Advanced Gastric Cancer After a D2 Dissection: A Retrospective Study.
Li Q; Li G; Palmer JD; Zhang Z
Am J Clin Oncol; 2017 Aug; 40(4):375-380. PubMed ID: 25503428
[TBL] [Abstract][Full Text] [Related]
18. Survival after adjuvant chemoradiotherapy or surgery alone in resectable adenocarcinoma at the gastro-esophageal junction.
Kofoed SC; Muhic A; Baeksgaard L; Jendresen M; Gustafsen J; Holm J; Bardram L; Brandt B; Brenø J; Svendsen LB
Scand J Surg; 2012; 101(1):26-31. PubMed ID: 22414465
[TBL] [Abstract][Full Text] [Related]
19. The patterns and timing of recurrence after curative resection for gastric cancer in China.
Liu D; Lu M; Li J; Yang Z; Feng Q; Zhou M; Zhang Z; Shen L
World J Surg Oncol; 2016 Dec; 14(1):305. PubMed ID: 27931221
[TBL] [Abstract][Full Text] [Related]
20. Populational trends and outcomes of postoperative radiotherapy for high-risk early-stage cervical cancer with lymph node metastasis: concurrent chemo-radiotherapy versus radiotherapy alone.
Matsuo K; Nusbaum DJ; Machida H; Huang Y; Khetan V; Matsuzaki S; Klar M; Grubbs BH; Roman LD; Wright JD
Am J Obstet Gynecol; 2020 May; 222(5):484.e1-484.e15. PubMed ID: 31678092
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
